Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Prothena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baseline Data from Phase 2 PASADENA Study of Prasinezumab (PRX002\/RG7935) in Parkinson's Disease to be Presented at AAT-AD\/PD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"IRELAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Prothena"},{"company":"Prothena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prothena Corporation Provides Update on Its Phase 2 PASADENA Study of Prasinezumab (PRX002\/RG7935) in Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"IRELAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Prothena"},{"company":"Prothena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prothena Announces Updated Timing of Presentation for Phase 2 PASADENA Study Results","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"IRELAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Prothena"},{"company":"Prothena","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche and Prothena will Advance Prasinezumab into Late-Stage Clinical Development Study in Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"IRELAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Prothena"},{"company":"Prothena","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Prothena Announces Achievement of $60 Million Milestone From Roche","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"IRELAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Prothena"},{"company":"Prothena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prothena Presents New Data for Alzheimer's and Parkinson's Disease Programs at AD\/PD 2022","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"IRELAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Prothena"}]

Prothena

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Prothena Presents New Data for Alzheimer's and Parkinson's Disease Programs at AD/PD 2022

Details:

Results showed that participants with PD who were treated with prasinezumab for two years showed slower decline of Movement Disorder Society-Unified Parkinson’s Disease Rating Scale Part 3 scores relative to participants treated with prasinezumab for one year.

Lead Product(s): Prasinezumab

Therapeutic Area: Neurology Product Name: RO7046015

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 16, 2022

ASK
US

Upload
your Pipeline Activity

Prothena

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Prothena Announces Achievement of $60 Million Milestone From Roche

Details:

Company has earned a $60 million milestone from its worldwide collaboration with Roche based on the first patient dosed in the Phase 2b PADOVA study of prasinezumab in patients with early Parkinson's disease.

Lead Product(s): Prasinezumab

Therapeutic Area: Neurology Product Name: PRX002

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: F. Hoffmann-La Roche

Deal Size: $60.0 million Upfront Cash: Undisclosed

Deal Type: Collaboration May 10, 2021

ASK
US

Upload
your Pipeline Activity

Prothena

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Roche and Prothena will Advance Prasinezumab into Late-Stage Clinical Development Study in Parkinson’s Disease

Details:

The study will be designed to further assess the efficacy of prasinezumab by expanding upon the patient population enrolled in PASADENA to include patients with early Parkinson’s disease on stable levodopa therapy.

Lead Product(s): Prasinezumab

Therapeutic Area: Neurology Product Name: RO7046015

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: F. Hoffmann-La Roche

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 20, 2020

ASK
US

Upload
your Pipeline Activity

Prothena

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Prothena Announces Updated Timing of Presentation for Phase 2 PASADENA Study Results

Details:

Company will present Part 1 of the Phase 2 PASADENA study of prasinezumab in early Parkinson’s disease. Results from Part 1 of the Phase 2 PASADENA study of prasinezumab were selected as an oral Top Abstract presentation at the upcoming Virtual 2020 MDS Congress.

Lead Product(s): Prasinezumab

Therapeutic Area: Neurology Product Name: RO7046015

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 03, 2020

ASK
US

Upload
your Pipeline Activity

Prothena

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Prothena Corporation Provides Update on Its Phase 2 PASADENA Study of Prasinezumab (PRX002/RG7935) in Parkinson’s Disease

Details:

The study did not achieve the primary goal, but did show signs of efficacy. Roche has begun further clinical development preparation and is reviewing the results from PASADENA Study Part 1.

Lead Product(s): Prasinezumab

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 22, 2020

ASK
US

Upload
your Pipeline Activity

Prothena

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Baseline Data from Phase 2 PASADENA Study of Prasinezumab (PRX002/RG7935) in Parkinson's Disease to be Presented at AAT-AD/PD

Details:

PASADENA is a two-part Phase 2 clinical study in patients with early Parkinson’s disease that is being conducted by Roche.

Lead Product(s): Prasinezumab

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 31, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY